JSPR
NASDAQJasper Therapeutics Inc.
Price$0.72-0.15 (-17.13%)
2026-05-212026-08-25
News · 26 weeks38-9%
2026-03-012026-08-23
Mix2690d
- Insider11(42%)
- SEC Filings10(38%)
- Other2(8%)
- M&A2(8%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form PRE 14A filed by Jasper Therapeutics Inc.PRE 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form 10-Q filed by Jasper Therapeutics Inc.10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAcquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) ("Jasper"), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter ended June 30, 2026, and provided a corporate update. "We are excited to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission o
- ANALYSTPiper Sandler initiated coverage on Jasper Therapeutics with a new price targetPiper Sandler initiated coverage of Jasper Therapeutics with a rating of Overweight and set a new price target of $2.00
- INSIDERSEC Form 4 filed by Director Wiggans Thomas G4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Emster Kurt Von4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Lucas Svetlana4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Crutcher Patrick J4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Shizuru Judith Anne4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- INSIDERSEC Form 3 filed by new insider Keenan Greg3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Ros Matthew E4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERNew insider Song Wenru claimed ownership of 3,150 units of Voting Common Stock and claimed ownership of 2,816 units of Non Voting Convertible Preferred Stock (SEC Form 3)3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ros Matthew E3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERSEC Form 4 filed by Director Crutcher Patrick J4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- INSIDERNew insider Crutcher Patrick J claimed ownership of 518,331 units of Voting Common Stock (SEC Form 3)3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- PRJasper Therapeutics Announces Merger with Kira PharmaceuticalsCombined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones REDWOOD CITY, Calif. and CAM
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Jasper Therapeutics Inc.SCHEDULE 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
- SECSEC Form DEFA14A filed by Jasper Therapeutics Inc.DEFA14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECSEC Form DEF 14A filed by Jasper Therapeutics Inc.DEF 14A - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
- SECJasper Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
JSPR FAQ
7 questionsWhat does Jasper Therapeutics Inc. do?
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company develops JSP191, a humanized monoclonal antibody for clearing hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It also develops Jasper eHSC Platform to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.Where does JSPR stock trade?
Jasper Therapeutics Inc. (JSPR) is listed on NASDAQ.What sector and industry is JSPR in?
Jasper Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Jasper Therapeutics Inc. go public?
Jasper Therapeutics Inc. (JSPR) completed its IPO in 2020.What are analysts saying about JSPR?
Jasper Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Piper Sandler: Overweight with a $200.00 price target on 2026-08-12.What companies are similar to JSPR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare JSPR side-by-side with any of them on Quantisnow.How can I track JSPR on Quantisnow?
Quantisnow aggregates Jasper Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow JSPR to receive live email and push alerts on every new disclosure.